From: The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods
Antimicrobial category | ECDC-MDR | KRINKO-3MRGN | KRINKO-4MRGN | UHZ-MDR |
---|---|---|---|---|
Antipseudomonal penicillins | Piperacillin/ tazobactam or ticarcillin/ clavulanic acid | Piperacillin a) | Piperacillin a) | Piperacillin/ tazobactam |
Extended spectrum cephalosporins | Cefotaxime or ceftriaxone or ceftazidime or cefepime | Cefotaxime b) or ceftazidime | Cefotaxime b) or ceftazidime | Ceftazidime and cefepime |
Carbapenems | Imipenem or meropenem or doripenem | Imipenem or meropenem | Imipenem or meropenem | Imipenem or meropenem |
Quinolones | Ciprofloxacin or levofloxacin | Ciprofloxacin | Ciprofloxacin | Ciprofloxacin and levofloxacin |
Aminoglycosides | Amikacin or gentamicin or tobramycin or netilmicin | ≥2 of: Amikacin, gentamicin, tobramycin | ||
Folate pathway inhibitors | Trimethoprim/ sulphamethoxazol | |||
Penicillins plus beta-lactamase-inhibitors | Ampicillin/ sulbactam | |||
Polymyxins | Colistin or polymyxin B | |||
Tetracyclines | Tetracycline or doxycycline or minocycline | |||
Definition of MDR | Resistant to ≥3 categories | Resistant to antipseudomonal penicillin and cephalosporin-group and quinolone and susceptible to carbapenems | Resistant to all 4 categories or If a carbapenem is resistant all Acinetobacter are interpreted as 4MRGN or Acinetobacter with carbapenemase production | Resistant to 3 out of 5 categories |